These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 21375166)

  • 21. Good efficacy of drug-eluting balloons in a mixed population of patients with coronary artery disease.
    Cuculi F; Young M; Beeler R; Schoenenberger AW; Erne P
    J Invasive Cardiol; 2012 Apr; 24(4):151-3. PubMed ID: 22477748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of drug-eluting balloon (pre- or post-) dilation on neointima formation in de novo lesions treated by bare-metal stent: the IN-PACT CORO trial.
    Burzotta F; Brancati MF; Trani C; Pirozzolo G; De Maria G; Leone AM; Niccoli G; Porto I; Prati F; Crea F
    Heart Vessels; 2016 May; 31(5):677-86. PubMed ID: 25863804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of Long-Term Outcomes After Drug-Eluting Balloon Angioplasty for Bare-Metal Stent Restenosis.
    Hsieh MJ; Huang YC; Yeh JK; Chen CC; Chen DY; Yang CH; Tsai ML; Ho MY; Chang SH; Wang CY; Lee CH; Hsieh IC
    Heart Lung Circ; 2018 May; 27(5):588-594. PubMed ID: 28625598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between tissue characteristics assessed with optical coherence tomography and mid-term results after percutaneous coronary intervention for in-stent restenosis lesions: a comparison between balloon angioplasty, paclitaxel-coated balloon dilatation, and drug-eluting stent implantation.
    Tada T; Kadota K; Hosogi S; Miyake K; Ohya M; Amano H; Izawa Y; Kanazawa T; Kubo S; Ichinohe T; Hyoudou Y; Hayakawa Y; Sabbah MM; Otsuru S; Hasegawa D; Habara S; Tanaka H; Fuku Y; Katoh H; Goto T; Mitsudo K
    Eur Heart J Cardiovasc Imaging; 2015 Oct; 16(10):1101-11. PubMed ID: 25762559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-eluting balloon versus bare-mental stent and drug-eluting stent for de novo coronary artery disease: A systematic review and meta-analysis of 14 randomized controlled trials.
    Cui K; Lyu S; Song X; Yuan F; Xu F; Zhang M; Wang W; Zhang D; Dai J
    PLoS One; 2017; 12(4):e0176365. PubMed ID: 28445555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis.
    Habara S; Iwabuchi M; Inoue N; Nakamura S; Asano R; Nanto S; Hayashi Y; Shiode N; Saito S; Ikari Y; Kimura T; Hosokawa J; Nakamura M; Kotani J; Kozuma K; Mitsudo K
    Am Heart J; 2013 Sep; 166(3):527-33. PubMed ID: 24016503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-coated balloons for de novo coronary lesions: results from the Valentines II trial.
    Waksman R; Serra A; Loh JP; Malik FT; Torguson R; Stahnke S; von Strandmann RP; Rodriguez AE
    EuroIntervention; 2013 Sep; 9(5):613-9. PubMed ID: 24058077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One-year clinical outcomes of percutaneous treatment with drug-eluting balloons: results from a multicenter registry.
    Calé R; Sousa PJ; Pereira E; Araújo Gonçalves P; Vitorino S; Vinhas H; Raposo L; Martins C; Mesquita Gabriel H; Campante Teles R; Sousa Almeida M; Pereira H; Mendes M
    Rev Port Cardiol; 2013 May; 32(5):361-9. PubMed ID: 23601968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of bifurcation lesions with a drug-eluting balloon: the PEPCAD V (Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease) trial.
    Mathey DG; Wendig I; Boxberger M; Bonaventura K; Kleber FX
    EuroIntervention; 2011 May; 7 Suppl K():K61-5. PubMed ID: 22027730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Late Restenosis After Paclitaxel-Coated Balloon Angioplasty Occurs in Patients With Drug-Eluting Stent Restenosis.
    Habara S; Kadota K; Shimada T; Ohya M; Amano H; Izawa Y; Kubo S; Hyodo Y; Otsuru S; Hasegawa D; Tada T; Tanaka H; Fuku Y; Goto T; Mitsudo K
    J Am Coll Cardiol; 2015 Jul; 66(1):14-22. PubMed ID: 26139053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Late clinical outcomes for SeQuent please paclitaxel-coated balloons in PCI of instent restenosis and de novo lesions: A single-center, real world registry.
    Hee L; Terluk A; Thomas L; Hopkins A; Juergens CP; Lo S; French JK; Mussap CJ
    Catheter Cardiovasc Interv; 2017 Feb; 89(3):375-382. PubMed ID: 27113534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomised clinical trial.
    Adriaenssens T; Dens J; Ughi G; Bennett J; Dubois C; Sinnaeve P; Wiyono S; Coosemans M; Belmans A; D'hooge J; Vrolix M; Desmet W
    EuroIntervention; 2014 Aug; 10(4):439-48. PubMed ID: 25138182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fractional flow reserve-guided paclitaxel-coated balloon treatment for de novo coronary lesions.
    Shin ES; Ann SH; Balbir Singh G; Lim KH; Kleber FX; Koo BK
    Catheter Cardiovasc Interv; 2016 Aug; 88(2):193-200. PubMed ID: 26423017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: Patient-level pooled analysis of Korean Multicenter in-Stent Restenosis Registry.
    Lee JM; Rhee TM; Hahn JY; Hwang D; Park J; Park KW; Kim HL; Kim SH; Chae IH; Doh JH; Jeon KH; Choi YJ; Park JS; Choi SH; Gwon HC; Koo BK; Alfonso F; Kim HS
    Int J Cardiol; 2017 Mar; 230():181-190. PubMed ID: 28043660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SeQuentPlease World Wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study.
    Wöhrle J; Zadura M; Möbius-Winkler S; Leschke M; Opitz C; Ahmed W; Barragan P; Simon JP; Cassel G; Scheller B
    J Am Coll Cardiol; 2012 Oct; 60(18):1733-8. PubMed ID: 23040575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coronary artery treatment with paclitaxel-coated balloon using a BTHC excipient: clinical results of the international real-world DELUX registry.
    Toelg R; Merkely B; Erglis A; Hoffman S; Bruno H; Kornowski R; Slagboom T; Naber C; Witzenbichler B; Graf K; Richardt G; Hehrlein C;
    EuroIntervention; 2014 Sep; 10(5):591-9. PubMed ID: 24345357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions.
    Grube E; Chevalier B; Smits P; Džavík V; Patel TM; Mullasari AS; Wöhrle J; Stuteville M; Dorange C; Kaul U;
    JACC Cardiovasc Interv; 2011 Feb; 4(2):168-75. PubMed ID: 21349455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.